Experience

Pillar Biosciences Incorporated
• United States
• Biotechnology
• 1 - 100 Employee
• Board Member

  • Aug 2021 - Present

The National Institutes of Health
• United States
• Biotechnology Research
• 700 & Above Employee
• Team Lead, COVID-19 Rapid Acceleration of Diagnostics (RADx) Initiative

  • May 2020 - Present

Independent
• Uganda
• International Trade and Development
• 1 - 100 Employee
• Retired and Enjoying Life

  • Oct 2017 - Present


Takeda

• Biotechnology
• 1 - 100 Employee

• Senior Vice President, Genomic Medicine

  • Oct 2016 - Sep 2017

• Senior Vice President and Head of Pharmacogenomics

  • Jun 2012 - Sep 2016



Gen Probe

• Senior Vice President, R&D

  • Feb 2009 - Nov 2011

  Head of Research and Development Head of Research and Development



GlaxoSmithKline

• United States
• Investment Management

• VP, Pharmacogenetics

  • Aug 2006 - Jun 2008

  Vice President responsible for the line management of 70 scientists to support the following global PGx activities and projects: -Sample management (Phase I – IV) and the implementation of two fully automated DNA storage systems for 2 million samples. -Design and Standard for genetic studies and Pharmacogenetics projects. -Large scale case/control whole genome screen PGx studies. -DNA genotyping (internal platforms, technology development, external alliances and experimental coordinations). -Large scale whole genome wide informatics data management -Genetics data analysis Show less

• VP, Discovery and Pipeline Genetics

  • Aug 2003 - Jul 2006

  line manage of 140 scientists to support all phases of R&D activities and projects including: -Sample management (Phase I – IV). -Design, planning and implementation of the automated DNA storage system. -Design and Standard for genetic studies and Pharmacogenetics projects. -Large scale case/control whole genome screen PGx studies. -DNA genotyping (internal platforms, technology development, external alliances and experimental coordinations). -DNA sequencing. -Large scale whole genome wide informatics data management -Genetics data analysis Show less

• VP, High Capability SNP Technology

  • Jan 2000 - Jul 2003

  Served as a cross-matrix VP with no direct reports for three years. Scientific leader and coordinator of experimental activities across all genetics/genomics areas. Responsible for the vision of the project, planning and execution of all experimental phases and activities including coordination with clinical matrix team, clinical operation teams, medicine test development team, commercial matrix teams, legal and CIP consultants. Led as many as 40 scientists at various times to identify the genetic association of HLA-5701 and abacavir associated hypersensitivity reactions. The timing and the robustness of the internal GSK results prevented the pre-mature regulatory restriction on the marketing and sale of abacavir. (Publication # 51 and Pending patent # US20070148641A9) Show less

• Dept Head, Molecular Genetics, Genetics Research

  • Mar 1998 - Jan 2000

• Group Leader, Molecular Genetics, Genetics Research

  • May 1995 - Feb 1998

  • Leader in the development of SNP-based marker set for linkage analysis.• Established ACeDB and other bioinformatic tools at GlaxoWellcome to organize human disease gene mapping. Design and development of an alias table for integration of genetic, physical and expression maps.• Develop a high throughput system for large scale SNP discovery.



University of North Carolina at Chapel Hill

• Research
• 1 - 100 Employee

• Assistant Professor of Pharmacology

  • Mar 1989 - May 1995

  • Constructed the first human chromosome specific bacterial artificial library. • Constructed the first human chromosome specific bacterial artificial library.